SPTLC2 mediates AKT pathway and regulates the biological function of Ovarian Cancer
Ovarian cancer is a leading cause of death among gynecologic malignancies. This disappointing prognosis is closely related to intrinsic or acquired resistance to conventional platinum-based chemotherapy, which can affect a third of patients. As such, investigating relevant molecular targets is crucial in the fight against this disease. So far, many mutations involved in ovarian cancer pathogenesis have been identified. Among them, a few pathways were implicated. One such pathway is the P13K/AKT/mTOR with abnormalities found in many cases. This pathway is considered to have an instrumental role in proliferation, migration, invasion and, more recently, in chemotherapy resistance. Serine Palmitoyltransferase (SPTLC2) have been found to influence P13K/AKT/mTOR pathway with different potential role in tumor genesis behavior. In particular, their biological function was recently investigated as regards chemoresistance, therefore, leading to the identification of potential specific indirect biomarker of platinum sensitivity in ovarian cancer Overall design: Ovarian Cancer Hey-A8 cells with stable knockdown of SPTLC2 and shCON as a negative control.  shCON and shSPTLC2 cells were extracted for RNA sequencing